Hiroshi Nakamura
Chuo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Relationship between the Montgomery-Åsberg Depression Rating Scale and Sheehan Disability Scale in patients with bipolar depressive episodes.
Journal: International journal of psychiatry in clinical practice
Published: September 22, 2025
A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression.
Journal: Neuropsychopharmacology reports
Published: November 18, 2022
Early improvement as a predictor of later response to lurasidone in schizophrenia from Japan trials: A diagnostic test.
Journal: Psychiatry and clinical neurosciences
Published: March 25, 2022
Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
Journal: Journal of child and adolescent psychopharmacology
Published: February 08, 2022
Early improvement as a predictor of response to blonanserin transdermal patch in patients with schizophrenia.
Journal: Schizophrenia research
Published: December 06, 2021
Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study.
Journal: Journal of child and adolescent psychopharmacology
Published: October 06, 2021
Differences in the incidence of lurasidone adverse events between depressive disorders and schizophrenia in double-blind, randomized, placebo-controlled trials: a meta-analysis.
Journal: Psychopharmacology
Published: April 20, 2021
Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies.
Journal: Annals of general psychiatry
Published: January 02, 2021
Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.
Journal: Journal of pharmacological sciences
Published: July 14, 2020
Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
Journal: CNS drugs
Published: December 29, 2019
Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
Journal: Neuropsychopharmacology reports
Published: February 13, 2019
Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.
Journal: Neuropsychopharmacology reports
Published: November 19, 2018
Last Updated: 09/26/2026